Long-term outcomes of different bortezomib-based regimens in Chinese myeloma patients

Bortezomib has significantly increased the response rates in multiple myeloma (MM), but optimal bortezomib-based regimens for initial MM therapy have not yet been defined. We retrospectively compared the outcomes of 128 patients newly diagnosed with symptomatic MM who received either bortezomib comb...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hua, Wang, Liang, Lu, Yue, Chen, Xiaoqin, Geng, Qirong, Wang, Weida, Xia, Zhongjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4734823/
https://www.ncbi.nlm.nih.gov/pubmed/26869803
http://dx.doi.org/10.2147/OTT.S97457

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4734823/
https://www.ncbi.nlm.nih.gov/pubmed/26869803
http://dx.doi.org/10.2147/OTT.S97457

Ejemplares similares